Afamelanotide (Scenesse®) is not recommended for use within NHSScotland for prevention of phototoxicity in adults with erythropoietic protoporphyria

The submitting company’s justification of the treatment’s cost in relation to its benefits was not sufficient and a sufficiently robust clinical and economic analysis was not provided. Until further data becomes available, it can be prescribed within the ultra-orphan pathway.

Source:

Scottish Medicines Consortium